Tag: transthyretin amyloidosis treatment market analysis

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Transthyretin Amyloidosis Treatment Market from 2024 to 2033?

The transthyretin amyloidosis treatment market has experienced strong growth, forecasted to reach $5.52 billion in 2024 from $5.07 billion in 2023 at a CAGR of 8.9%. Key growth contributors include increased disease awareness, advancements in diagnostics, drug development, patient advocacy, and collaborative research.

The transthyretin amyloidosis treatment market is set to grow significantly, reaching $7.42 billion by 2028 with a CAGR of 7.7%. Growth is driven by an expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, and improved treatment access. Trends include the emergence of combination therapies, strategic drug development partnerships, targeting peripheral and cardiac manifestations, patient education programs, and the incorporation of real-world evidence in treatment guidelines.

Claim Your Free Sample of the Global Transthyretin Amyloidosis Treatment Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp

What Key Factors Are Fueling the Growth of the Transthyretin Amyloidosis Treatment Market?

Rising investments in research and development are expected to propel the growth of the transthyretin amyloidosis treatment market. Increased funding in R&D allows for the discovery of new treatments for transthyretin amyloidosis, a rare and progressive disease. For example, Alnylam Pharmaceuticals increased its R&D investment by 11.49% in 2022, highlighting the growing commitment to finding effective treatments. This trend in R&D investment will continue to drive the transthyretin amyloidosis treatment market.

What Are the Major Segments of the Transthyretin Amyloidosis Treatment Market?

1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs

3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

What New Trends Are Transforming the Transthyretin Amyloidosis Treatment Market?

Companies in the transthyretin amyloidosis treatment market are focusing on orphan drugs for specialized conditions. In March 2023, Ionis Pharmaceuticals received FDA approval for Eplontersen, an orphan drug aimed at treating familial transthyretin-mediated amyloid, a progressive polyneuropathy condition. Eplontersen targets the production of transthyretin protein, helping treat both hereditary and non-hereditary forms of amyloidosis.

Order Now for Fast Delivery of Your Transthyretin Amyloidosis Treatment Market Report!

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Which Regions Are Driving Growth in the Transthyretin Amyloidosis Treatment Market?

North America was the largest region in the transthyretin amyloidosis treatment market in 2023. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Transthyretin Amyloidosis Treatment Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the transthyretin amyloidosis treatment market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Transthyretin Amyloidosis Treatment Market Include

1. Transthyretin Amyloidosis Treatment Market Executive Summary

2. Transthyretin Amyloidosis Treatment Market Segments

3. Transthyretin Amyloidosis Treatment Market Size And Template Market Growth Rate

4. Key Transthyretin Amyloidosis Treatment Market Trends

5. Major Transthyretin Amyloidosis Treatment Market Drivers

……

25. Key Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market

26. Top Transthyretin Amyloidosis Treatment Companies

27. Transthyretin Amyloidosis Treatment Market Opportunities And Strategies

28. Transthyretin Amyloidosis Treatment Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Pediatric Bladder Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

Reversible Airway Diseases Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/reversible-airway-diseases-treatment-global-market-report

Urothelial Carcinoma Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The transthyretin amyloidosis treatment market has witnessed robust growth in recent years, with significant expansion anticipated in the coming years. This growth can be attributed to several key factors:

• Increased Disease Awareness: Efforts to raise awareness about transthyretin amyloidosis have led to early detection and diagnosis, driving treatment demand.
• Advancements in Diagnostic Tools: Technological advancements have improved diagnostic capabilities, facilitating prompt identification of the condition.
• Drug Development and Approvals: The development and approval of novel drugs and therapies have expanded the treatment landscape, offering more options for patients.
• Patient Advocacy and Support: Advocacy groups and support networks have played a crucial role in empowering patients and driving demand for improved treatments.
• Collaboration in Research: Collaborative efforts among stakeholders, including healthcare providers, researchers, and pharmaceutical companies, have accelerated research and development initiatives.

Projected Market Growth

The transthyretin amyloidosis treatment market is poised for continued growth, with projections indicating a steady rise in market size:

• 2023-2024: The market is expected to grow from $5.07 billion in 2023 to $5.52 billion in 2024, reflecting a compound annual growth rate (CAGR) of 8.9%.
• 2024-2028: Further growth is anticipated, with the market projected to reach $7.42 billion by 2028, at a CAGR of 7.7%.

Emerging Trends and Drivers

Several trends and drivers are expected to shape the future landscape of the transthyretin amyloidosis treatment market:

• Expanded Therapeutic Pipeline: Ongoing research and development efforts are expanding the therapeutic pipeline, paving the way for the development of new treatment modalities.
• Increased Genetic Screening: Advances in genetic screening technologies are enabling early detection of transthyretin amyloidosis, facilitating timely intervention.
• Global Awareness Initiatives: Global efforts to raise awareness about rare diseases, including transthyretin amyloidosis, are enhancing disease recognition and treatment access.
• Personalized Medicine Approaches: Tailored treatment approaches based on individual patient characteristics are gaining prominence, optimizing treatment outcomes.
• Improved Treatment Access: Efforts to improve access to treatment, particularly in underserved regions, are widening the patient pool and driving market growth.

Read More On The Transthyretin Amyloidosis Treatment Market Report 2024 – https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Major Companies Driving Innovation

Several key players are driving innovation and shaping the trajectory of the transthyretin amyloidosis treatment market:

• Pfizer Inc.
• Abbvie Inc.
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Novo Nordisk A/S
• Merck & Co. Inc.
• Astellas Pharma Inc.
• Alnylam Pharmaceuticals Inc.
• And many more.

Innovative Orphan Drug Combinations

Major companies are focusing on developing innovative orphan drug combinations to address unmet medical needs in transthyretin amyloidosis treatment:

• Eplontersen: An orphan drug designed specifically for transthyretin amyloidosis, offering targeted therapeutic benefits.
• FDA Approval: Regulatory approvals, such as FDA approval for Eplontersen, underscore the significance of orphan drugs in advancing treatment options.
• Strategic Partnerships: Collaborative efforts between industry stakeholders are driving the development and commercialization of orphan drug combinations.

Mergers and Acquisitions

Mergers and acquisitions are reshaping the competitive landscape of the transthyretin amyloidosis treatment market:

• Novo Nordisk AS Acquisition: Novo Nordisk AS’s acquisition of the ATTR Amyloidosis Program from Prothena Corporation PLC highlights strategic initiatives aimed at bolstering product portfolios and expanding market presence.

Segmentation Overview

The transthyretin amyloidosis treatment market is segmented based on various parameters, including type, drug, therapy, and distribution channel:

1. Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2. Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3. Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4. Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Insights

North America emerged as the largest region in the transthyretin amyloidosis treatment market in 2023, underscoring the region’s significant market share and strategic importance.

In conclusion, the transthyretin amyloidosis treatment market is poised for substantial growth, driven by increased research and development investments, innovation in orphan drug combinations, strategic collaborations, and expanding market segmentation. As the market continues to evolve, stakeholders must adapt to emerging trends and capitalize on opportunities to address the unmet needs of patients with transthyretin amyloidosis.

Request for A Sample Of The Global Transthyretin Amyloidosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/sample_request?id=13129&type=smp